Sinil Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	8,323	9,313	4,643	7,519	4,944	7,340
Short-Term Investments	29,971	29,900	29,070	15,900	18,410	13,530
Cash & Short-Term Investments	38,294	39,214	33,713	23,419	23,354	20,870
Cash Growth	7.69%	16.31%	43.96%	0.28%	11.90%	43.01%
Accounts Receivable	20,437	19,551	20,248	21,878	23,420	20,588
Other Receivables	697.89	721.11	590.8	967.33	293.28	133.52
Receivables	21,135	20,272	20,839	22,845	23,713	20,721
Inventory	25,329	23,009	22,861	22,492	20,188	16,700
Prepaid Expenses	26.49	27.71	28.18	27.45	19.92	24.67
Other Current Assets	38.44	32.55	7.52	3.85	6.05	110.3
Total Current Assets	84,823	82,555	77,449	68,787	67,280	58,427
Property, Plant & Equipment	42,948	42,645	44,789	41,916	35,744	30,999
Long-Term Investments	882.55	882.43	726.62	839.01	966.42	1,512
Other Intangible Assets	2,358	2,382	1,736	1,810	1,870	1,801
Long-Term Accounts Receivable	-0	0	-	-	-	-
Long-Term Deferred Tax Assets	2,663	2,569	2,413	2,097	1,944	1,804
Other Long-Term Assets	38,186	38,455	38,698	36,960	34,978	34,381
Total Assets	171,860	169,489	165,861	152,460	142,832	128,974
Accounts Payable	5,328	4,913	5,356	5,455	6,807	4,967
Accrued Expenses	1,147	1,067	897.02	901.59	824.11	734.16
Current Portion of Leases	140.72	143.94	164.45	165.01	135.5	133.75
Current Income Taxes Payable	125.2	370.94	2,161	267.59	2,105	486.48
Other Current Liabilities	8,523	8,170	7,875	7,355	6,088	5,702
Total Current Liabilities	15,263	14,665	16,453	14,145	15,959	12,023
Long-Term Leases	107.92	139.26	268.23	379.12	3.98	139.48
Pension & Post-Retirement Benefits	2,241	1,882	2,364	2,394	2,560	2,387
Other Long-Term Liabilities	461.9	453.09	270.53	646.79	1,031	1,228
Total Liabilities	18,074	17,139	19,356	17,565	19,554	15,777
Common Stock	5,993	5,993	5,993	5,993	5,771	5,609
Additional Paid-In Capital	1,170	1,170	1,170	1,170	1,170	1,170
Retained Earnings	147,706	146,269	140,444	128,688	117,118	106,663
Treasury Stock	-1,358	-1,358	-1,358	-1,358	-1,285	-1,180
Comprehensive Income & Other	275	275	256.8	402.28	503.25	934.27
Shareholders' Equity	153,786	152,350	146,506	134,895	123,277	113,196
Total Liabilities & Equity	171,860	169,489	165,861	152,460	142,832	128,974
Total Debt	248.64	283.19	432.68	544.13	139.48	273.22
Net Cash (Debt)	38,045	38,931	33,281	22,875	23,214	20,597
Net Cash Growth	8.19%	16.98%	45.49%	-1.46%	12.71%	45.04%
Net Cash Per Share	-	3367.83	2879.07	1978.43	2086.88	1832.18
Filing Date Shares Outstanding	-	11.56	11.56	11.56	11.12	11.24
Total Common Shares Outstanding	-	11.56	11.56	11.56	11.12	11.24
Working Capital	69,560	67,890	60,996	54,643	51,321	46,403
Book Value Per Share	-	13179.53	12673.99	11669.56	11082.32	10069.36
Tangible Book Value	151,428	149,968	144,769	133,085	121,407	111,395
Tangible Book Value Per Share	-	12973.46	12523.79	11512.97	10914.20	9909.14
Land	2,094	2,094	2,094	2,094	2,094	2,094
Buildings	38,552	38,239	36,456	34,193	28,429	19,865
Machinery	54,568	54,547	50,582	47,680	17,654	6,877
Construction In Progress	1,535	167.4	3,056	125	4,994	1,463